Hilde Grens

Hilde Grens

Auto-generated profile, based on publicly available information

Hilde Grens

Department of Obstetrics and Gynaecology, Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in Human Reproduction Open
Verified
Journal Article
Open access
PDF file
WLWiep R de Ligny
Wiep R de Ligny
KFKathrin Fleischer
Kathrin Fleischer
HGHilde Grens
Hilde Grens
DBDidi D M Braat
Didi D M Braat
JBJan Peter de Bruin
Jan Peter de Bruin
What is the evidence for over-the-counter antioxidant supplements for male infertility? Less than half of over-the-counter antioxidant supplements for male fertility patients have been tested in a clinical trial, and the available clinical trials are generally of poor quality. The prevalence of male infertility is rising and, with this, the market for supplements claiming to improve male fertility is expanding. Up to now, there is limited data on the evidence for these over-the-counter supplements. Amazon, Google Shopping and other relevant shopping websites were searched on 24 June 2022 with the following terms: ‘supplements’, ‘antioxidants’, ‘vitamins’, AND ‘male fertility’, ‘male infertility’, ‘male subfertility’, ‘fertility men’, ‘fertility man’. All supplements with a description of ingredients in English, Dutch, French, Spanish, or German were included. Subsequently, Pubmed and Google Scholar were searched for studies that included the supplements. Inclusion criteria were supplements with antioxidant properties, of which the main purpose was to improve male fertility. Included supplements must be available without a doctor’s prescription. Supplements containing plant extracts were excluded, as well as supplements of which the content or dosage was not clear. The ingredients, dosage, price and health claims of the supplements were recorded. We assessed whether substances in the supplements exceeded the recommended dietary allowance (RDA) or tolerable upper intake level (UL). All clinical trials and animal studies investigating included supplements were selected for this review. Clinical trials were assessed for risk of bias with a risk of bias tool appropriate for the study design. There were 34 eligible antioxidant supplements found, containing 48 different active substances. The average price per 30 days was 53.10 US dollars. Most of the supplements (27/34, 79%) contained substances in a dosage exceeding the recommended daily allowance (RDA). All manufacturers of the supplements made health claims related to the improvement of sperm quality or male fertility. For 13 of the 34 supplements (38%), published clinical trials were available, and for one supplement, only an animal study was found. The overall quality of the included studies was poor. Only two supplements were tested in a good quality clinical trial. As a consequence of searching shopping websites, a comprehensive search strategy could not be formulated. Most supplements were excluded because they contained plant extracts or because supplement information was not available (in an appropriate language). This is the first review that gives an insight into the market of male fertility supplements as available to infertility patients and other men seeking to improve their fertility. Earlier reviews have focused only on supplements with published clinical trials. However, we show that more than half of the supplements have not been tested in a clinical trial. To our knowledge, this review is the first to assess the dosage of supplements in relation to the RDA. In agreement with the literature, we found that the evidence on male fertility supplements is generally of poor quality. This review should urge pharmaceutical companies to evaluate their products in randomized controlled trials in order to provide people with substantiated information. The research position of W.R.d.L. is funded by an unrestricted grant from Goodlife Pharma. W.R.d.L., K.F., and J.P.d.B. are in the research team of a clinical trial on Impryl®, one of the supplements included in this review. N/A.

16 February 2022 in Human Reproduction Open
Verified
Journal Article
Open access
PDF file
EBE T I A Buisman
E T I A Buisman
HGH Grens
H Grens
RWR Wang
R Wang
SBSohinee Bhattacharya
Sohinee Bhattacharya
DBD D M Braat
D D M Braat
JSJ W van der Steeg
J W van der Steeg
What is the methodological validity and usefulness of randomized controlled trials (RCTs) on pain relief during oocyte retrieval for IVF and ICSI? Key methodological characteristics such as randomization, allocation concealment, primary outcome measure and sample size calculation were inadequately reported in 33–43% of the included RCTs, and a broad heterogeneity is revealed in the studied outcome measures. A Cochrane review on conscious sedation and analgesia for women undergoing oocyte retrieval concluded that the overall quality of evidence was low or very low, mainly owing to poor reporting. This, and heterogeneity of studied outcome measures, limits generalizability and eligibility of results for meta-analysis. For this review, a systematic search for RCTs on pain relief during oocyte retrieval was performed on 20 July 2020 in CENTRAL CRSO, MEDLINE, Embase, PsycINFO, CINAHL, ClinicalTrials.gov, WHO ICTRP, Web of Science, Portal Regional da BVS and Open Grey. RCTs with pain or patient satisfaction as an outcome were included and analysed on a set of methodological and clinical characteristics, to determine their validity and usefulness. Screening of 2531 articles led to an inclusion of 51 RCTs. Randomization was described inadequately in 33% of the RCTs. A low-risk method of allocation concealment was reported in 55% of the RCTs. Forty-nine percent of the RCTs reported blinding of participants, 33% of blinding personnel and 43% of blinding the outcome assessor. In 63% of the RCTs, the primary outcome was stated, but a sample size calculation was described in only 57%. Data were analysed according to the intention-to-treat principle in 73%. Treatment groups were not treated identically other than the intervention of interest in 10% of the RCTs. The primary outcome was intraoperative pain in 28%, and postoperative pain in 2%. The visual analogue scale (VAS) was the most used pain scale, in 69% of the RCTs in which pain was measured. Overall, nine other scales were used. Patient satisfaction was measured in 49% of the RCTs, for which 12 different methods were used. Occurrence of side-effects and complications were assessed in 77% and 49% of the RCTs: a definition for these was lacking in 13% and 20% of the RCTs, respectively. Pregnancy rate was reported in 55% of the RCTs and, of these, 75% did not adequately define pregnancy. To improve the quality of future research, we provide recommendations for the design of future trials. These include use of the VAS for pain measurement, use of validated questionnaires for measurement of patient satisfaction and the minimal clinically relevant difference to use for sample size calculations. Consensus has not been reached on some methodological characteristics, for which we formulated recommendations. To prevent further heterogeneity in research on this topic, recommendations were formulated based on expert opinion, or on the most used method thus far. Future research may provide evidence to base new recommendations on. Use of the recommendations given for design of trials on this topic can increase the generalizability of future research, increasing eligibility for meta-analyses and preventing wastefulness. No specific funding was obtained for this study. S.B. reports being the editor-in-chief of Human Reproduction Open. For this manuscript, he was not involved with the handling process within Human Reproduction Open, or with the final decision. Furthermore, S.B. reports personal fees from Remuneration from Oxford University Press as editor-in-chief of Human Reproduction Open, personal fees from Editor and contributing author, Reproductive Medicine for the MRCOG, Cambridge University Press. The remaining authors declare no conflict of interest in relation to the work presented. Not applicable.

19 September 2020 in Neurourology and Urodynamics
Verified
Journal Article
Open access
PDF file
WPWilke M. Post
Wilke M. Post
ARAlejandra Ruiz-Zapata
Alejandra Ruiz-Zapata
HGHilde Grens
Hilde Grens
RVRob B. M. de Vries
Rob B. M. de Vries
GPGeert Poelmans
Geert Poelmans
KKKirsten B. Kluivers
Kirsten B. Kluivers
Aim: To perform a systematic review summarizing the knowledge of genetic variants, gene, and protein expression changes in humans and animals associated with urgency urinary incontinence (UUI) and to provide an overview of the known molecular mechanisms related to UUI.Methods: A systematic search was performed on March 2, 2020, in PubMed, Embase, Web of Science, and the Cochrane library. Retrieved studies were screened for eligibility. The risk of bias was assessed using the ROBINS‐I (human) and SYRCLE (animal) tool. Data were presented in a structured manner and in the case of greater than five studies on a homogeneous outcome, a meta‐analysis was performed.Results: Altogether, a total of 10,785 records were screened of which 37 studies met the inclusion criteria. Notably, 24/37 studies scored medium‐high to high on risk of bias, affecting the value of the included studies. The analysis of 70 unique genes and proteins and three genome‐wide association studies showed that specific signal transduction pathways and inflammation are associated with UUI. A meta‐analysis on the predictive value of urinary nerve growth factor (NGF) levels showed that increased urinary NGF levels correlate with UUI.Conclusion: The collective evidence showed the involvement of two molecular mechanisms (signal transduction and inflammation) and NGF in UUI, enhancing our understanding of the pathophysiology of UUI. Unfortunately, the risk of bias was medium‐high to high for most studies and the value of many observations remains unclear. Future studies should focus on elucidating how deficits in the two identified molecular mechanisms contribute to UUI and should avoid bias.

7 February 2022 in JMIR Formative Research
Verified
Journal Article
Open access
HGHilde Grens
Hilde Grens
JBJan Peter de Bruin
Jan Peter de Bruin
AHAleida Huppelschoten
Aleida Huppelschoten
JKJan A M Kremer
Jan A M Kremer
Background: Due to the COVID-19 pandemic, major parts of elective health care in the Netherlands, such as reproductive medicine, were paused. When health care was resumed, video consultation was used as a new solution to continue consultations with the new governmental rules of social distancing. Prior to this COVID-19 situation, video consultation was not used extensively in the Netherlands; therefore, physicians and patients are not familiar with this way of consultation. Objective: The purpose of this study was to measure the level of patient centeredness and shared decision making in infertile couples who have undergone fertility workup through video consultation. Methods: This is a questionnaire study with an additional qualitative part for a more in depth understanding. Infertile couples (ie, male and female partners with an unfulfilled wish for a child after 1 year of unprotected intercourse) were referred to a fertility center and underwent fertility workup through video consultation. The fertility workup consisted of 2 separate video consultations, with diagnostic tests according to a protocol. After the last video consultation couples received a digital questionnaire, which consisted of a modified version of the Patient-Centered Questionnaire-Infertility (PCQ-I) and CollaboRATE questionnaire. Fifty-three eligible infertile couples were approached, and of these, 22 participated. Four women were approached for a semistructured interview. Results: The median score on the modified PCQ-I (scale of 0 to 3) was 2.64. The highest rating was for the subscale communication and information, and the lowest rating was for the subscale organization of care. The median score on the CollaboRATE questionnaire (scale of 1 to 9) was 8 for all 3 subquestions. Patients mentioned privacy, less travel time, and easy use of the program as possible benefits of video consultation. However, patients preferred the first consultation with their physician to be face-to-face consultation as video consultation was considered less personal. Conclusions: The high levels of patient centeredness and shared decision making show that video consultation is a promising way of providing care remotely, although attention has to be payed to mitigate the more impersonal setting of video consultation when compared with face-to-face consultation.

5 June 2024 in Reproductive BioMedicine Online
Verified
Journal Article
Closed access
HGHilde Grens
Hilde Grens
AHAleida G. Huppelschoten
Aleida G. Huppelschoten
WLWiep R. De Ligny
Wiep R. De Ligny
RKRudolf B. Kool
Rudolf B. Kool
JKJan A.M. Kremer
Jan A.M. Kremer
JBJan-Peter de Bruin
Jan-Peter de Bruin

24 April 2025 in Fertility and Sterility
Verified
Journal Article
Open access
HGHilde Grens
Hilde Grens
AHAleida G. Huppelschoten
Aleida G. Huppelschoten
JKJan A.M. Kremer
Jan A.M. Kremer
JBJan-Peter de Bruin
Jan-Peter de Bruin
To study whether an online fertility workup with video consultation, is non-inferior to a regular consultation with face-to-face contact in terms of patient centeredness and shared decision making. A non-blinded randomized controlled single-center trial SUBJECTS: New, treatment naïve infertile patients INTERVENTION: The online fertility workup consists of online recommendations for diagnostic tests (based on an anamnesis questionnaire) and performing the tests before a 30-minute video consultation as compared to a hospital-based fertility workup with face-to-face appointments. The study interventions took place during the COVID-19 pandemic. The primary outcome measure for this study was the level of patient centeredness as measured with the Patient-Centredness Questionnaire-Infertility. Secondary outcome measures were, amongst others, the level of 'Shared decision making' as measured with the CollaboRATE questionnaire and information on waiting times and technical issues. For more in-depth and qualitative information about the online fertility workup, semi-structured interviews were held. The mean patient centeredness score was 2.66 for the online workup group with video consultation versus 2.56 for the control group, on a scale of 0-3. The mean difference of the total score and the different subscales varied between 0.01 and 0.1 and thus meeting the non-inferiority criteria of 0.3 There were no significant differences in the experienced levels of shared decision making between the two groups. The majority of the intervention group had a preparation time of less than five minutes, while more than half of the control group spend 60-90 minutes on their appointment in the hospital. In 17% of the video consultations there were some technical issues. During the interviews, patients expressed positive experiences with the online workup and video consultation in different themes, for example the patient-physician relationship, expressing their emotions and communication. However, some expressed their preference to a face-to-face consultation for 'bad news'. This study showed that an online fertility workup with video consultation is non-inferior to a regular fertility work-up in terms of patient centeredness and shared decision making. Important advantages of an online fertility workup were the reduced travel time and patients' feelings of a more personalized and discrete healthcare setting and possibilities for more sustainable healthcare options.